An investigator-initiated clinical study of GPN02006 developed by Grand Pharmaceutical Group (HKG:0512) in cooperation with two other parties for the diagnosis of hepatocellular carcinoma recently achieved a milestone breakthrough, a Tuesday Hong Kong bourse filing said.
The clinical results showed the drug exhibits "excellent" safety and imaging efficacy, as well as high-quality imaging 30 minutes post administration.
The drug was developed in cooperation with Wuhan Ruidifu Biotechnology and JECHO Biopharmaceuticals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。